Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19
Phase 2
- Conditions
- Covid19
- Interventions
- Drug: intranasal ivermectin spray
- Registration Number
- NCT04716569
- Lead Sponsor
- South Valley University
- Brief Summary
Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the nose and post nasal space may help in early management of covid19 and may play a great rule in prophylaxis as well
- Detailed Description
150 patient with early covid is devided into two groups first group will receive regular protocol of drugs second group will receive ivermectin nasal spray in addition to regular protocl of drugs
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- early covid19 pateints
Exclusion Criteria
- children and pregnant women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description intranasal Ivermectin group intranasal ivermectin spray Ivermectin group Patients who will receive intranasal ivermectin Control group intranasal ivermectin spray patients who will receive regular protocol drugs
- Primary Outcome Measures
Name Time Method progression of covid 19 clinical picture [ Time Frame: within 14 days after enrollement ] progress of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)with radiological assesment and blood tests
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zaky Aref
🇪🇬Qinā, Qina, Egypt